Active substance    ravalizumab
Holder Alexion Pharma Belgium
Status Running
Indication the treatment of atypical Haemolytic Uremic Syndrome in patients who completed the Open Label Extension of the phase III studies ALXN1210-aHUS-311 and ALXN1210-aHUS-312 (EudraCT Nr: 2016-002027-29) and ALXN1210-aHUS-312 (EudraCT Nr: 2016-002499-29)
Public documents Approbation
  Information for the patient
  Informed consent
Last update 10/07/2023


Last updated on 27/11/2023